Involved in the regulation of cell survival. Promotes invasive migration of cells in which it functions to localize and maintain integrin alpha-V/beta-1 at the tips of extending pseudopodia. Increases the rates of ovarian and breast cancers progression and aggressiveness by modulating cellular processes such as proliferation, survival and migration of epithelial tumor cells. May selectively regulate the apical recycling pathway. Together with MYO5B regulates transcytosis. Interacts with RAB11FIP1, RAB11FIP2, RAB11FIP3 and RAB11FIP4. Interacts (via the hypervariable C-terminal region) with ITGB1 (via the cytoplasmic region); the interaction is GTP- dependent. Interacts with ITGAV. Associates with the integrin alpha-V/beta-1 heterodimer. Expressed in ovarian epithelium (NOE) and breast tissue. Expressed in ovarian cancer; expression is increased relative to NOE cells. Expression in ovarian cancer is stage dependent, with stage III and stage IV showing higher levels than early stage cancers. Expressed in breast cancer; expression is increased relative to normal breast tissue. Belongs to the small GTPase superfamily. Rab family. Note: This description may include information from UniProtKB.
Protein type: G protein, monomeric; G protein, monomeric, Rab
Molecular Function: GTPase activity; protein binding; GDP binding; GTP binding; myosin V binding
Biological Process: intracellular protein transport; exocytosis; metabolic process; positive regulation of cell proliferation; Rab protein signal transduction; melanosome transport; pseudopodium organization and biogenesis
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.